Bharat Parenterals Yönetim

Yönetim kriter kontrolleri 2/4

Bharat Parenterals' CEO is Bharatkumar Desai, appointed in Sep 2014, has a tenure of 10.17 years. directly owns 11.37% of the company’s shares, worth ₹1.06B. The average tenure of the management team and the board of directors is 6.3 years and 6.8 years respectively.

Anahtar bilgiler

Bharatkumar Desai

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	10.2yrs
CEO sahipliği	11.4%
Yönetim ortalama görev süresi	6.3yrs
Yönetim Kurulu ortalama görev süresi	6.8yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Bharatkumar Desai'un ücretlendirmesi Bharat Parenterals'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-₹28m
Jun 30 2024	n/a	n/a	₹83m
Mar 31 2024	n/a	n/a	₹145m
Dec 31 2023	n/a	n/a	₹252m
Sep 30 2023	n/a	n/a	₹243m
Jun 30 2023	n/a	n/a	₹228m
Mar 31 2023	₹14m	₹14m	₹157m
Dec 31 2022	n/a	n/a	₹180m
Sep 30 2022	n/a	n/a	₹165m
Jun 30 2022	n/a	n/a	₹145m
Mar 31 2022	₹14m	₹14m	₹213m
Dec 31 2021	n/a	n/a	₹189m
Sep 30 2021	n/a	n/a	₹230m
Jun 30 2021	n/a	n/a	₹215m
Mar 31 2021	₹13m	₹13m	₹204m
Dec 31 2020	n/a	n/a	₹256m
Sep 30 2020	n/a	n/a	₹283m
Jun 30 2020	n/a	n/a	₹260m
Mar 31 2020	₹14m	₹14m	₹241m
Dec 31 2019	n/a	n/a	₹222m
Sep 30 2019	n/a	n/a	₹207m
Jun 30 2019	n/a	n/a	₹208m
Mar 31 2019	₹14m	₹14m	₹212m
Dec 31 2018	n/a	n/a	₹167m
Sep 30 2018	n/a	n/a	₹134m
Jun 30 2018	n/a	n/a	₹117m
Mar 31 2018	₹3m	₹3m	₹91m

Tazminat ve Piyasa: Insufficient data to establish whether Bharatkumar's total compensation is reasonable compared to companies of similar size in the Indian market.

Tazminat ve Kazançlar: Bharatkumar's compensation has increased whilst the company is unprofitable.

CEO

Bharatkumar Desai (60 yo)

10.2yrs

Görev süresi

₹14,336,875

Tazminat

Mr. Bharatkumar Rameshchandra Desai serves as Chairman of Bharat Parenterals Limited and serves as its Director since September 30, 1992. He has been with Bharat Parenterals Limited since September 30, 199...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Bharatkumar Desai	Chairman & MD	10.2yrs	₹14.34m	11.37% ₹ 1.1b
Jignesh Shah	Chief Financial Officer	6.3yrs	₹1.03m	Veri yok
Krutika Bhattbhatt	Company Secretary & Compliance Officer	1.1yrs	Veri yok	Veri yok
Nikita Desai	Marketing Manager	no data	Veri yok	Veri yok
Himaben Desai	President of Commercial	no data	₹200.00m	12.01% ₹ 1.1b
Hemang Shah	Executive Director	no data	₹2.59m	Veri yok

6.3yrs

Ortalama Görev Süresi

Deneyimli Yönetim: 541096's management team is seasoned and experienced (6.3 years average tenure).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Bharatkumar Desai	Chairman & MD	32.2yrs	₹14.34m	11.37% ₹ 1.1b
Hemang Shah	Executive Director	14.3yrs	₹2.59m	Veri yok
Shaileshkumar Gabhawala	Independent Non-Executive Director	7.3yrs	₹20.00k	Veri yok
Zankhana Sheth	Independent Non-Executive Director	6.3yrs	₹20.00k	Veri yok
Sanjay Shah	Non Executive Director	4.1yrs	₹10.00k	Veri yok
Mukeshbhai Patel	Non-Executive Independent Director	4.2yrs	₹20.00k	0.0015% ₹ 142.6k

6.8yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 541096's board of directors are considered experienced (6.8 years average tenure).

Bharat Parenterals Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Bharat Parenterals Limited, Annual General Meeting, Jul 02, 2024

Bharat Parenterals Limited, Annual General Meeting, Jul 02, 2024

Insufficient new directors

Bharat Parenterals Limited, Annual General Meeting, Sep 30, 2023

Bharat Parenterals Limited, Annual General Meeting, Sep 30, 2023

Bharat Parenterals Limited, Annual General Meeting, Sep 27, 2022

Recent updates

Second quarter 2025 earnings released: ₹27.00 loss per share (vs ₹6.07 profit in 2Q 2024)

Bharat Parenterals Limited to Report Q2, 2025 Results on Oct 29, 2024

First quarter 2025 earnings released: ₹14.71 loss per share (vs ₹13.03 profit in 1Q 2024)

Bharat Parenterals Limited to Report Q1, 2025 Results on Aug 08, 2024

Bharat Parenterals Limited to Report Q1, 2025 Results on Aug 08, 2024

Bharat Parenterals Limited (BSE:541096) agreed to acquire an unknown majority stake in Varenyam Biolifesciences Private Limited for INR 22.56 million.

Upcoming dividend of ₹1.00 per share

Bharat Parenterals Limited, Annual General Meeting, Jul 02, 2024

Bharat Parenterals Limited, Annual General Meeting, Jul 02, 2024

New minor risk - Shareholder dilution

New minor risk - Market cap size

Full year 2024 earnings released: EPS: ₹24.94 (vs ₹42.14 in FY 2023)

Bharat Parenterals Limited to Report Q4, 2024 Results on May 22, 2024

Bharat Parenterals Limited announced that it expects to receive INR 981.500535 million in funding

Bharat Parenterals Limited announced that it expects to receive INR 981.500535 million in funding

Investor sentiment improves as stock rises 16%

New major risk - Share price stability

Investor sentiment improves as stock rises 15%

Investor sentiment deteriorates as stock falls 17%

Investor sentiment improves as stock rises 19%

Third quarter 2024 earnings released: EPS: ₹6.45 (vs ₹4.94 in 3Q 2023)

Bharat Parenterals Limited to Report Q3, 2023 Results on Feb 13, 2024

Investor sentiment improves as stock rises 24%

Second quarter 2024 earnings released: EPS: ₹6.07 (vs ₹17.19 in 2Q 2023)

Insufficient new directors

Bharat Parenterals Limited Declares Dividend for the Financial Year 2022 to 2023

Bharat Parenterals Limited, Annual General Meeting, Sep 30, 2023

Bharat Parenterals Limited, Annual General Meeting, Sep 30, 2023

Investor sentiment improves as stock rises 34%

New minor risk - Share price stability

First quarter 2024 earnings released: EPS: ₹13.03 (vs ₹2.03 in 1Q 2023)

Bharat Parenterals Limited to Report Q1, 2024 Results on Aug 09, 2023

Bharat Parenterals Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023

Bharat Parenterals Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023

Full year 2023 earnings released: EPS: ₹28.40 (vs ₹36.68 in FY 2022)

Bharat Parenterals Limited to Report Q4, 2023 Results on May 20, 2023

Third quarter 2023 earnings released: EPS: ₹4.94 (vs ₹2.32 in 3Q 2022)

Investor sentiment deteriorated over the past week

Second quarter 2023 earnings released: EPS: ₹17.19 (vs ₹13.88 in 2Q 2022)

Bharat Parenterals Limited, Annual General Meeting, Sep 27, 2022

First quarter 2023 earnings released: EPS: ₹2.03 (vs ₹13.49 in 1Q 2022)

Full year 2022 earnings released: EPS: ₹36.67 (vs ₹35.59 in FY 2021)

Investor sentiment improved over the past week

Bharat Parenterals Limited to Report Q4, 2022 Results on May 28, 2022

Investor sentiment improved over the past week

Now 20% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2022 earnings released: EPS ₹13.88 (vs ₹11.26 in 2Q 2021)

Full year 2021 earnings released: EPS ₹35.59 (vs ₹42.14 in FY 2020)

Investor sentiment improved over the past week

Bharat Parenterals Limited Receives the License and Authorization from Drugs Controller General of India and Central Drugs Standard Control Organization, New Delhi

Investor sentiment improved over the past week

New 90-day low: ₹341

Third quarter 2021 earnings released: EPS ₹9.46 (vs ₹14.11 in 3Q 2020)

New 90-day low: ₹345

New 90-day low: ₹365

Bharat Parenterals Limited Approves Appointment of Lubhanshi Jhalani as Company Secretary and Compliance Officer

Bharat Parenterals Limited Announces Resignation of Monica Ahir, Company Secretary

New 90-day high - ₹457

First quarter earnings released

Bharat Parenterals Limited to Report Q1, 2021 Results on Aug 20, 2020

New 90-day high - ₹422

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi